MARINA DEL REY, Calif., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Atlas Therapeutics Corporation (OTCBB:ATTH), the manufacturer of the innovative myostatin inhibitor, MYO-T12(R), has announced that it will be sponsoring Daniel "Ikemen" Gracie, of the world famous Gracie family, in his first fight in a new weight class (185) this Saturday, October 15, 2011, at Bellator 54 in Atlantic City.
Gracie, a two-time World Champion, is part of the Gracie Family, who is often referred to as the First Family of MMA. He trained under Carlinhos Gracie and received his Black Belt at the age of 23. Gracie is a two-time World Champion in Brazilian Jiu-Jitsu and has garnered several other titles in his career. He is an MMA PRIDE and IFL veteran as well. Today, Gracie trains with Carlon Colker, M.D., who is widely regarded as one of the world's foremost experts on wellness, physical performance, athletic enhancement, and performance nutrition and is the formulator of MYO-T12 (www.MYOT12.com). Thus far, Gracie has seen outstanding results from MYO-T12 and credits it to helping him make the weight-class move.
"I was introduced to MYO-T12 by Dr. Carlon Colker. He explained that this supplement will enable my body to shed fat and build muscle while training and cutting weight," Gracie said. "I started immediately and saw the results just as fast. I was able to cut 20 pounds, build more muscle and build more strength. My workouts are more intense and the recovery time afterward is considerably shorter. I feel amazing and MYO-T12 is the ultimate supplement for me!"
JB Bernstein, CEO of Atlas Therapeutics, commented, "We are honored to be able to support Daniel Gracie. His accomplishments in his career are truly amazing, and his experience with MYO-T12 is yet another example of how superior performance and MYO-T12 go hand in hand."
MYO-T12 is the world's first clinically validated, myostatin-inhibiting dietary supplement. Myostatin is a protein naturally produced in our bodies which inhibits muscle growth and which increases as we age. MYO-T12 provides individuals a healthier method for building and maintaining lean muscle and reaching their fitness goals by reducing the body's levels of myostatin to allow one's natural growth hormones to perform at maximum efficiency. The supplement has been clinically proven to reduce average serum myostatin levels in the body by up to 46 percent within 12-18 hours after just one serving. For information, go to: www.MYOT12.com
ATLAS THERAPEUTICS CORPORATION
Atlas Therapeutics has acquired MYO-T12®, the world's only clinically validated Myostatin modulator. Myostatin is a natural regulatory protein which inhibits muscle growth and recovery. MYO-T12® is manufactured to optimize biological activity and has the potential to redefine existing standards of physical enhancement. Atlas is focused on preserving and growing the existing brand identity of MYO-T12® by refining its technical profile, and designing and implementing a marketing and sales strategy to increase penetration of the product into the existing health and fitness community.
For more information on Atlas Therapeutics Corporation, visit www.AtlasTherapeutics.com/">www.AtlasTherapeutics.com.
The Atlas Therapeutics Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10042
Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.